Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
GlobeNewswire Inc.
•
•By Na
Crinetics Pharmaceuticals announced a conference call scheduled for January 5, 2026 to provide a commercialization update on PALSONIFY (paltusotine) and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. The company's lead product PALSONIFY is the first once-daily oral treatment approved by the FDA for acromegaly, while atumelnant is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.